Avalo Therapeutics (AVTX) Change in Accured Expenses (2014 - 2026)

Avalo Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 12.06% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 692.49% YoY), and the FY2025 full-year result was $6.7 million, up 699.64% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from $5.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.4 million in Q4 2025, with the low at -$4.9 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$507294.1 across 5 years, with a median of -$856000.0 in 2024.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 726.21% — and 2025, when it surged 435.54%.
• Avalo Therapeutics' Change in Accured Expenses stood at -$488000.0 in 2022, then sank by 96.72% to -$960000.0 in 2023, then soared by 204.06% to $999000.0 in 2024, then surged by 435.54% to $5.4 million in 2025, then plunged by 127.94% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $5.4 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.